Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ChemoCentryx completes Series C financing
October 2006
by Randall C. Willis  |  Email the author
SHARING OPTIONS:

MOUNTAIN VIEW, Calif.—On the same day that it announced the signing of a major research col­laboration with GSK (see story), ChemoCentryx announced it completed $17.7 million in Series C financing. When added to the $63.5 million in upfront fund­ing it will receive from GSK and other financing vehicles, ChemoCentryx has achieved about $90 million in new mon­ies in 2006.
 
"Historically, we have suc­cessfully pursued a mix of venture capital financing and non-dilutive funding," said Dr. Thomas J. Schall, company president and CEO, in a pre­pared statement. "The combi­nation of our Series C financ­ing and the upfront payments received as part of our strategic alliance with GSK reinforces this long-term strategy. We are now extremely well-positioned to avail ourselves of market opportunities of our choosing, as we continue to build value in ChemoCentryx and our pipe­line of chemokine-based medicines."
 
The Series C investors include Jennison Associates, HBM BioVentures, Orbimed Advisors, Techne Corporation, Alta Partners and GIMV.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.